TY - JOUR T1 - PEPFAR Spending Types and Reduction in HIV Infection Rates JF - medRxiv DO - 10.1101/2022.11.14.22282303 SP - 2022.11.14.22282303 AU - Stephen Walker Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/11/21/2022.11.14.22282303.abstract N2 - Since 2004, PEPFAR has invested over $100 billion in fighting HIV, primarily targeting sub-Saharan Africa. This study examines the effectiveness of spending types as defined by the program. In this study, I take the spending data published by PEPFAR that was categorized into key focus areas that include (1) Care & Treatment, (2) Testing, (3) Prevention, (4) Socioeconomic, and (5) Above-site, Program Management and Other, and estimate the effectiveness of these categories on a key outcome variable: new HIV infections. I also estimate the same regressions along two dimensions: (1) pre and post PEPFAR 2.0 that was implemented in 2014, and (2) the 12 sub-Saharan focus countries versus the non-sub-Saharan countries. Data was collected from public sources including PEPFAR, the GHO, and the World Bank and a total of $61.5 billion in spending was identified from 2005-2021 covering 54 target countries.Main Outcome(s) and Measure(s) The marginal dollar spent on prevention activities experienced the highest incremental effect of reducing new HIV infections in targeted countries from 2005-2021. The coefficient on Prevention spending was -0.715 (t-stat of -2.83), which was highly significant at the 1 percent level. However, much of this effect was driven by pre-2014 spending before PEPFAR 2.0 was implemented. Post 2014, socioeconomic programs were measured to have the greatest marginal effect driven by non-sub-Saharan countries. Overall effectiveness of spending increased post PEPFAR 2.0 for non-Sub-Saharan countries but declined for sub-Saharan countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -